US Patent 12116371 Substituted pyridines as irreversible inhibitors of menin-MLL interaction
Patent 12116371 was granted and assigned to Biomea Fusion, Inc. on October, 2024 by the United States Patent and Trademark Office.
All edits
Edits on 17 Oct, 2024
Golden AI
Edits made to:
Infobox (+25 properties)
Article (+601 characters)
US Patent 12116371 Substituted pyridines as irreversible inhibitors of menin-MLL interaction
Article
Patent abstract
Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins. Also described are specific irreversible inhibitors of menin-MLL interaction. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the menin-MLL irreversible inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia and other diseases or conditions dependent on menin-MLL interaction.
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
Patent Inventor Names
Brendan Kelly0
Edward Painter0
Jim Palmer0
Matthew Welsch0
Ravi Upasani0
Sridhar Vempati0
Thomas Butler0
Date of Patent
October 15, 2024
0Patent Application Number
182286020
Date Filed
July 31, 2023
0Patent Citations
Patent Primary Examiner
Find more entities like US Patent 12116371 Substituted pyridines as irreversible inhibitors of menin-MLL interaction
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.